Novavax shares rose about 11% before the opening bell after the company also said it filed for emergency use of the vaccine in Canada and the European Medicines Agency.
For Indonesia, the vaccine will be manufactured by the world’s largest vaccine maker, Serum Institute, and sold under the Indian company’s brand name, Covovax.
Novavax said initial shipments to Indonesia are expected to begin imminently.
The country is expected to receive 20 million doses of the protein-based vaccine this year, according to the government.
Penny Lukito, head of Indonesia’s National Food and Drug Control Agency, did not immediately respond to a request for comment from Reuters.
So far, Novavax has applied for EUA in various countries, including the UK, Australia, India and the Philippines.
The company, along with its Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a deployment in Japan early next year.
Novavax and Serum Institute have jointly committed to deliver more than 1.1 billion doses to the COVAX facility, co-managed by the World Health Organization. Delivery of the vaccine will begin this year after obtaining a WHO emergency use list and will continue until 2022.
Novavax delayed the application for approval in the United States at the end of this year, and Politico announced last month that the company had encountered production and quality issues.
Novavax shot has been shown to be over 90% effective, including against a variety of worrying variants of the coronavirus in a large, late stage clinical trial based in the United States.